AVNS Avanos Medical (AVNS) Insider Trading, Ownership & Congress Trades
Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0001606498
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
142
13F, latest reported quarter
Avanos Medical insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for AVANOS MEDICAL, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 6, 2025.
- The trade is 0.4% of the 83,860 shares held after it.
- No other insider sold within 30 days.
- 142 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Commercial Officer Holbrook Kerr sold about $3.4K of AVNS on Nov 18, 2025; 142 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 6, 2025.
- The trade is 0.1% of the 84,926 shares held after it.
- No other insider sold within 30 days.
- 142 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Commercial Officer Holbrook Kerr sold about $1.1K of AVNS on Nov 18, 2025; 142 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 6, 2025.
- The trade is 16.3% of the 85,026 shares held after it.
- No other insider sold within 30 days.
- 142 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Commercial Officer Holbrook Kerr sold about $152.2K of AVNS on Nov 18, 2025, the largest insider sale at the company on our record; 142 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 6, 2025.
- The trade is 0.9% of the 84,165 shares held after it.
- No other insider sold within 30 days.
- 142 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Commercial Officer Holbrook Kerr sold about $8.4K of AVNS on Nov 18, 2025; 142 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 21.8% of the 91,593 shares held after it.
- No other insider bought within 30 days.
- 142 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BLACKFORD GARY bought about $219.6K of AVNS on Aug 13, 2025, the largest insider purchase at the company on our record; 142 funds added in the latest 13F quarter.18 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
142 funds bought in last quarter
more than 74% of Medical Devices
Revenue
+1.9% year over year
below 72% of Medical Devices
Margin
-10.4% net margin
more than 56% of Medical Devices
Buybacks
$1.3M repurchased, FY to 2026-03-31
below 86% of Medical Devices
Short interest
no short interest reported
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch AVNS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns AVNS: institutional holders (13F)
13F holdings, latest reported quarter
7,468,794 sh
$185.8M
2,177,366 sh
$54.2M
2,010,691 sh
$50.0M
1,993,794 sh
$49.6M
1,668,329 sh
$41.5M
Congress trades in AVNS
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
AVNS planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
AVNS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Nexpoint Merger Arbitrage Fund
$51.6M position · as of 2026-06-30
3.5%
ProShares Merger ETF
$372.0K position · as of 2026-05-31
2.3%
AltShares Event-Driven ETF
$248.0K position · as of 2026-05-31
2.0%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$2.5M position · as of 2026-06-30
1.6%
First Trust Merger Arbitrage Fund
$25.2M position · as of 2026-06-30
1.5%
THE ARBITRAGE FUND
$12.3M position · as of 2026-05-31
1.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Joseph F. Woody
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$7.2M
$4.0M
$2.0M
-33%
+44%
2022
$6.9M
$3.0M
$1.7M
-20%
+39%
2021
$5.5M
$411.4K
$1.3M
+3%
+48%
2020
$7.6M
$11.2M
$1.6M
+36%
+16%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 142 funds added last quarter. Each figure is a federal filing, dated the day it went public.
AVNS financials
Revenue growth
+1.9%
XBRL, annual
Net margin
-10.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$715.9M
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM AVNS
| FY Dec 2025 | $701.2M |
| FY Dec 2024 | $687.8M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | $820.0M |
| FY Dec 2021 | $744.6M |
| Mar 2026 | $182.2M |
| Dec 2025 | $180.9M |
| Sep 2025 | $177.8M |
| Jun 2025 | $175.0M |
| Mar 2025 | $167.5M |
| Dec 2024 | $179.6M |
| Sep 2024 | $170.4M |
| Jun 2024 | $171.7M |
At each fiscal year end
Single quarter
Net margin, TTM
-10.4%
net income over revenue, 2025-04-01 to 2026-03-31
Net margin, TTM AVNS
| FY Dec 2025 | -10.4% |
| FY Dec 2024 | -57.0% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +6.2% |
| FY Dec 2021 | +0.8% |
| Mar 2026 | +2.8% |
| Dec 2025 | -0.7% |
| Sep 2025 | -0.8% |
| Jun 2025 | -43.9% |
| Mar 2025 | +3.9% |
| Dec 2024 | -221.2% |
| Sep 2024 | +2.5% |
| Jun 2024 | +1.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$7.5M
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Free cash flow, TTM AVNS
| FY Dec 2025 | $43.1M |
| FY Dec 2024 | $82.9M |
| FY Dec 2023 | $14.6M |
| FY Dec 2022 | $71.6M |
| FY Dec 2021 | $66.3M |
| Mar 2026 | -$16.6M |
| Dec 2025 | $21.3M |
| Sep 2025 | $7.0M |
| Jun 2025 | -$4.2M |
| Mar 2025 | $19.0M |
| Dec 2024 | $53.1M |
| Sep 2024 | $20.0M |
| Jun 2024 | $21.9M |
At each fiscal year end
Single quarter
Debt to equity
0.11x
LongTermDebt as filed 2026-03-31 (includes the current portion); equity 2026-03-31
Debt to equity AVNS
| FY Dec 2025 | 0.12x |
| FY Dec 2024 | 0.15x |
| FY Dec 2023 | 0.13x |
| FY Dec 2022 | 0.18x |
| FY Dec 2021 | 0.10x |
| Mar 2026 | 0.11x |
| Dec 2025 | 0.12x |
| Sep 2025 | 0.12x |
| Jun 2025 | 0.12x |
| Mar 2025 | 0.12x |
| Dec 2024 | 0.15x |
| Sep 2024 | 0.12x |
| Jun 2024 | 0.13x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.42x
TTM operating cash flow over LongTermDebt as filed 2026-03-31 (includes the current portion)
Cash flow to debt AVNS
| FY Dec 2025 | 0.83x |
| FY Dec 2024 | 0.80x |
| FY Dec 2023 | 0.20x |
| FY Dec 2022 | 0.39x |
| FY Dec 2021 | 0.67x |
| Mar 2026 | 0.42x |
| Dec 2025 | 0.83x |
| Sep 2025 | 1.12x |
| Jun 2025 | 1.18x |
| Mar 2025 | 1.37x |
| Dec 2024 | 0.80x |
| Sep 2024 | 0.36x |
| Jun 2024 | 0.37x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-9.2%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on equity AVNS
| FY Dec 2025 | -9.1% |
| FY Dec 2024 | -38.0% |
| FY Dec 2023 | -4.9% |
| FY Dec 2022 | +3.9% |
| FY Dec 2021 | +0.5% |
| Mar 2026 | -9.2% |
| Dec 2025 | -9.1% |
| Sep 2025 | -46.7% |
| Jun 2025 | -46.4% |
| Mar 2025 | -37.2% |
| Dec 2024 | -38.0% |
| Sep 2024 | +1.3% |
| Jun 2024 | +0.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-6.9%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets AVNS
| FY Dec 2025 | -6.5% |
| FY Dec 2024 | -27.5% |
| FY Dec 2023 | -3.6% |
| FY Dec 2022 | +3.0% |
| FY Dec 2021 | +0.4% |
| Mar 2026 | -6.9% |
| Dec 2025 | -6.5% |
| Sep 2025 | -34.4% |
| Jun 2025 | -34.4% |
| Mar 2025 | -27.8% |
| Dec 2024 | -27.5% |
| Sep 2024 | +0.9% |
| Jun 2024 | +0.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital AVNS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +2.2% |
| Jun 2024 | +0.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-6.7%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
Return on capital employed AVNS
| FY Dec 2025 | -6.5% |
| FY Dec 2024 | -32.4% |
| FY Dec 2023 | +0.3% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | -6.7% |
| Dec 2025 | -6.5% |
| Sep 2025 | -40.8% |
| Jun 2025 | -40.0% |
| Mar 2025 | -32.1% |
| Dec 2024 | -32.4% |
| Sep 2024 | +2.2% |
| Jun 2024 | +1.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing AVNS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 25.53x |
| FY Dec 2021 | 266.69x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 70.68x |
| Jun 2024 | 117.18x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.2B
market value at close 2026-07-24 on 2026-04-28 shares, plus LongTermDebt as filed 2026-03-31 (includes the current portion), minus cash 2026-03-31
Enterprise value AVNS
| FY Dec 2025 | $521.8M |
| FY Dec 2024 | $749.2M |
| FY Dec 2023 | $1.1B |
| FY Dec 2022 | $1.4B |
| FY Dec 2021 | $1.7B |
| Mar 2026 | $673.2M |
| Dec 2025 | $521.8M |
| Sep 2025 | $559.3M |
| Jun 2025 | $571.4M |
| Mar 2025 | $660.2M |
| Dec 2024 | $749.2M |
| Sep 2024 | $1.2B |
| Jun 2024 | $987.1M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+0.6%
TTM free cash flow over market value at close 2026-07-24
FCF yield AVNS
| FY Dec 2025 | +8.3% |
| FY Dec 2024 | +11.3% |
| FY Dec 2023 | +1.4% |
| FY Dec 2022 | +5.7% |
| FY Dec 2021 | +4.0% |
| Mar 2026 | +1.2% |
| Dec 2025 | +8.3% |
| Sep 2025 | +14.0% |
| Jun 2025 | +15.5% |
| Mar 2025 | +17.3% |
| Dec 2024 | +11.3% |
| Sep 2024 | +3.3% |
| Jun 2024 | +4.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing AVNS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 0.04x |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-07-24. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $701.2M | $687.8M | $673.3M | $820.0M |
| Gross profit | $353.9M | $381.3M | $379.7M | $394.2M |
| Operating income | -$61.6M | -$396.2M | $4.2M | $35.5M |
| Net income | -$72.9M | -$392.1M | -$61.8M | $50.5M |
| EPS (diluted) | -1.57 | -8.53 | -1.32 | 1.07 |
| Operating cash flow | $74.7M | $100.7M | $32.4M | $90.9M |
| Cash | $89.8M | $107.7M | $87.7M | $127.7M |
| Long-term debt | $90.3M | $125.3M | $159.4M | $226.3M |
| Buybacks | $3.3M | $12.8M | $19.1M | $45.5M |
SEC XBRL, fiscal years, as known on 2026-10-28
AVNS Stock Sonar score 5/7 axes
Find similar shapesCompareAVNS ranks highest on financial health (75th percentile) and institutional and government (74th), and lowest on risk and compliance (15th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
